Menene Digital CMC Consortium kuma menene ainihin daidaita shi?
Ƙungiya ce ta Amurka 501(c)(6) aikin sa-kai yana aiki kafin gasa, Mike Stapleton na QbDVision ne ya jagoranta tare da Achim Frauenschuh na Novartis a matsayin abokin hadin gwiwa., kuma yana daidaita samfuran ilimin da aka raba da musaya don abubuwan hannu maimakon kimiyyar asali (Ci gaban Magunguna & Bayarwa, 2026-10-06). Bayanin iyakarsa a bayyane yake cewa bai tsara ilimin kimiyya ba, dandamalin fasaha ko takamaiman hanyoyin aiki na kamfani, da wancan ilimin mallakar mallaka, tsarin ciki da ayyukan aiki na al'ada suna tsayawa lafiya (Digital CMC Consortium, 2026-10-09).
Wannan iyaka yana da mahimmanci ga yadda kuke karanta ƙaddamarwa. Ƙungiyar ba ta rubuta peptide monograph ba, hanyar kira ko ƙayyadaddun tsabta. Yana gina tsarin bayanan da aka tsara wanda ke ba da damar rikodin haɗin gwiwar mai ɗaukar nauyi, Sakamakon nazari na CDMO da bayanan cancantar rukunin yanar gizon suna bayyana ma'auni iri ɗaya a cikin sharuɗɗan iri ɗaya. Ƙaddamar da ɗaukar hoto suna suna canja wurin fasahar dijital da ingantaccen tsarin musanyar ilimi tsakanin masu tallafawa da CDMO a matsayin aikin farko mai amfani, tare da kayan aikin aiwatarwa da lambar a cikin iyaka (Ci gaban Magunguna & Bayarwa, 2026-10-06).
Iyakance shine ɓangaren da yawancin ƙungiyoyi ke ɓacewa. Kamar yadda na 9 Oktoba 2026, shafin haɗin gwiwar ya buga babu samfurin bayanai, babu sarrafa ƙamus, babu jarrabawar conformance kuma babu shata; yana ƙaddamar da daidaitattun ƙayyadaddun bayanai na dijital a cikin watanni shida na ƙaddamarwa (Digital CMC Consortium, 2026-10-09). Ƙungiyar kuma ba ta buga jerin abubuwan da suka dace ba, don haka iyakarta tana da faɗin CMC maimakon sanarwa game da peptides musamman. Yanayin gazawar yana ɗaukar ƙaddamarwa azaman ma'auni da zaku iya aiwatarwa a yau, lokacin alkawari ne game da abin da za a gina.
Menene ma'anar 'shirye-shiryen bayanai' don haɓaka peptide mai shirye-shirye musamman?
Ci gaban peptide na shirye-shiryen yana nufin bayanan da yawa sun gamsar da ma'anar MHRA na amincin bayanai, cikakke, m, m, amintacce kuma abin dogaro a duk tsawon rayuwar bayanan, da ɗaukar alaƙar da ke barin wurin karɓa ya sake gina yadda aka samar da kowane sakamako. MHRA tana saita ALCOA azaman Wanda ake iyawa, Mai yiwuwa, Na zamani, Asali kuma Madaidaici, tare da "+" rufe Complete, Daidaitawa, Dorewa kuma Akwai (Jagorar Mutuncin Bayanan MHRA GXP da Ma'anoni, Maris 2018).
Tsarin tsarin ba sabon abu bane. 21 CFR 11.10(e) yana buƙatar amintacce, na'ura mai kwakwalwa, hanyoyin tantance hatimi na lokaci waɗanda ke yin rikodin kwanan wata da lokacin shigarwar mai aiki da ayyukan da suka ƙirƙira, gyara ko share bayanan lantarki, tare da canje-canjen da ba su rufe bayanan da aka yi rikodin a baya, kuma ana kiyaye hanyoyin tantancewa aƙalla muddin bayanan da kansu (21 CFR 11.10, halin yanzu kamar na 2026-10-09). Sashe 11.10(a) yana buƙatar tabbatarwa tare da ikon gane bayanan da ba su da inganci ko da aka canza, kuma 11.10(c) yana buƙatar kariyar da ke ba da damar ingantaccen kuma a shirye don dawo da ita cikin tsawon lokacin riƙewa (21 Babban darajar CFR 11, halin yanzu kamar na 2026-10-09).
Ma'aji yana adana bayanai. Shirye-shiryen yana kiyaye alaƙar da ke tsakanin su. Dole ne a ƙidaya rikodin samar da tsari tare da tsari na musamman ko lambar shaida, kwanan wata da sanya hannu a lokacin da aka bayar, kuma dole ne ya rubuta kwanan wata da lokuta, ainihin manyan kayan aiki, ƙayyadaddun ganewa na kowane tsari ciki har da ma'auni, ma'auni da lambobi na albarkatun albarkatun kasa da tsaka-tsaki, sakamako na ainihi don sigogi masu mahimmanci, sakamakon gwajin da ake gudanarwa da kuma dakin gwaje-gwaje, ainihin yawan amfanin ƙasa, da duk wani sabani tare da kimantawa da bincikensa (WHO GMP don APIs, TRS 957 Annex 2, §6.51–6.52). Babban fayil na PDFs bai gamsar da wannan ba; saitin rikodin inda kowane filin ya nuna a batch, hanya da kayan aikin da ya samar da shi yana yi.
Me yasa bayanan ci gaban peptide matsala ce ta ci gaba maimakon matsalar ajiya?
Ma'auni yana canza haɗuwa, zafi da taro canja wuri, guduro hali, maida hankali da tsarkakewa loading. Tasirin su jeri ne- da kayan aiki masu dogara; sharhin da aka ambata bai kafa ingantaccen haɗin kai na duniya ba, zafin jiki gradients ko aggregation taro. Yi kimanta batches na matukin jirgi a ƙarƙashin ƙayyadadden yanayi.
Kowane ɗayan waɗannan lambobin ana iya fassarawa ne kawai akan rikodin matakin da ke gabansa. Siffar da aka gama haɗawa tana nufin komai ba tare da lambar zagayowar ba, da resin loading da kuma deprotection yanayi da ya samar da shi. Babban kololuwa babba yana nufin komai ba tare da gradient ba, ginshiƙi da ma'aunin tunani da aka yi amfani da shi don kiransa. Truncations daga gazawar haɗin gwiwar sun mamaye bayanan ɗanyen bayanan dogon jeri, kuma jerin sharewa suna tasowa daga rashin cikar haɗin gwiwa ko rashin cikawa, tare da duka haɗin gwiwa tare da manufa akan daidaitattun gradients (Hanyar Peptide, 2026-09-22). Rata a cikin sarkar baya rasa fayil; yana kawar da ikon tantancewa daga cikin waɗannan hanyoyin da suka haifar da sakamakon.
Bangaren nazari yana da tsari iri ɗaya. Tsafta shine sakamakon ma'auni mai yawa wanda aka auna ƙazanta na HPLC tare da juzu'i, ruwa, ragowar kaushi da sauran abubuwan da ba za a iya ƙone su ba, kuma ainihi yana buƙatar dabarun kothogonal kamar haɗin gwiwar HPLC tare da ma'aunin tunani, MS, Tsarin MS/MS, NMR ko nazarin amino acid (USP reference-misali takarda, 2023). Adadin ma'auni-ma'auni shine ƙarshe da aka zana daga ma'auni da yawa da aka ɗauka akan abu ɗaya a rana guda. Ajiye ƙarshe ba tare da ma'auni ba kuma shafin na gaba ba zai iya sake haifar da shi ba.
Menene mafi ƙarancin haɗin haɗin da aka saita don adadin peptide?
Binciken Peptide CMC ya dogara ne akan saitin rikodin wanda kashin baya shine abun ciki na samar da tsari a cikin WHO GMP don APIs §6.51-6.52, an shimfiɗa shi tare da takamaiman filayen peptide da Layer na gano kayan aiki. Rubutun WHO na buƙatar keɓantaccen mai gano tsari tare da kwanan wata da sa hannu, da takaddun kowane muhimmin mataki wanda ya ƙunshi kwanan wata da lokuta, manyan kayan aiki ainihi, ƙayyadaddun ganewa na kowane tsari ciki har da ma'auni, matakan da adadin adadin albarkatun kasa, tsaka-tsaki ko kayan da aka sake sarrafawa, sakamako na ainihi don sigogi masu mahimmanci, samfurin yi, sa hannun masu yin wasan kwaikwayo da masu kulawa, sakamakon gwajin da ake gudanarwa da kuma dakin gwaje-gwaje, ainihin yawan amfanin ƙasa, marufi da bayanin lakabi, duk wani sabani tare da kimantawa da bincike, da sakamakon gwajin saki (WHO GMP don APIs, TRS 957 Annex 2, §6.51–6.52).
Tushen guda ɗaya yana buƙatar rikodin samar da tsari don kowane matsakaici da API tare da cikakken bayani akan samarwa da sarrafa kowane tsari, duba kafin fitarwa don tabbatar da sigar daidai ce kuma ingantaccen ingantaccen haifuwa na jagorar samarwa (WHO GMP don APIs, TRS 957 Annex 2, §6.50). Bayanan kula da dakin gwaje-gwaje dole ne su ɗauki cikakken rikodin duk ɗanyen bayanan da aka samar yayin kowane gwaji, ciki har da jadawali, ginshiƙi da sifofi da aka gano da kyau don nuna takamaiman kayan da aka gwada, da kwanan wata da sa hannun mutum na biyu da ke tabbatar da ainihin bayanan an sake duba su don daidaito, cikawa da yarda (WHO GMP don APIs, TRS 957 Annex 2, §6.60).
|
Layer |
Filaye |
Anga |
|---|---|---|
|
Batch ainihi |
Batch ID na musamman, ranar fitowa, sa hannu, sigar koyarwar master |
WHO §6.51, §6.50 |
|
Magana |
Guduro, lodi, hadawa da kuma hana sake zagayowar, capping, lambar sake zagayowar |
WHO §6.52 |
|
Kayayyaki |
Danyen abu da matsakaicin adadin lambobi, nauyi, matakan, mai bayarwa |
WHO §6.52 |
|
Enkephalin Synthesis Gyara |
Shafin (N-lokaci, ragowar index, C-lokaci), rike, tabbacin orthogonal |
WHO §6.52 |
|
Ng Peptides Supplier Tsari |
Sakamako madaidaicin tsari, Jumla Masu Kayayyakin Peptide samfurin, sakamakon cikin aiwatarwa, yawa |
WHO §6.52 |
|
Bayanin ƙazanta |
Nau'o'i, lokacin riƙewa dangi, yanki %, shaida mai yawa, kaddara |
Hukumar Lafiya ta Duniya Fluorescent Peptide Synthesis §6.60 Peptides Supplier |
|
Saki |
Shaida, tsarki, abun ciki / net peptide, endotoxin, haihuwa |
WHO §6.52, §6.60 |
|
Kayan aiki Fmoc Chemistry Peptide Synthesis |
Kayayyakin kayan aikin, model da serial lambobi, software, aikace-aikace, database da kuma OS versions, matsayin cancanta |
USP <1058> 4Qs |
|
Bita |
Sa hannu na mutum na biyu, sabawa, Binciken OOS |
WHO §6.60, §6.61 |
USP <1058> yana ba da Layer kayan aiki ta hanyar ƙirar 4Qs, Zane, Shigarwa, Cancantar Ayyuka da Ayyuka, tare da PQ ta amfani da gwaje-gwajen dacewa na tsarin don nuna daidaiton aiki bisa ga ƙayyadaddun ƙayyadaddun amfani da aka yi niyya, da bayanan ganowa waɗanda suka haɗa da lissafin abubuwan da ke da ƙira da lambobi da software, aikace-aikace, database da kuma OS versions (LCGC, rashin kwanan wata). Wannan bene, ba takamaiman ba: babu saitin rikodin guda ɗaya da ya dace da kowane shiri, da takamaiman filayen peptide da ke sama ƙari ne ga kashin baya na WHO maimakon ƙa'idar da aka buga..
Yaya tsarki, ainihi, abun ciki / net peptide, kwanciyar hankali da dacewa da kima sun bambanta a cikin rikodin?
Takaddun bayanin martaba na ƙazanta na peptide yana kasawa galibi lokacin da tsabta, ainihi, abun ciki/net peptide da assay sun ruguje zuwa lamba ɗaya. Tsafta shine madaidaicin dangi na nau'ikan da ke da alaƙa da peptide a cikin chromatogram; abun ciki na peptide net shine juzu'in kayan da ke da peptide kwata-kwata, lissafin ruwa, Abubuwan da ake amfani da su kamar acetate da TFA, sauran kaushi da inorganic saura; An kafa ainihi ta hanyar orthogonal gami da NMR don fasalulluka, LC-MS/MS don taro da jeri, Amino-acid bincike don bambanta isoleucine daga leucine, da gwajin chirality don D-amino acid (USP reference-misali takarda, 2023).
Misalin aikin da aka buga ya nuna dalilin da yasa lissafin ke da mahimmanci. A cikin peptide tare da acetic acid azaman counterion da TFA azaman reagent kira, HPLC ƙazanta sun kasance 0.92% yankin da aka gano gabaɗaya, acetic acid 5.58% w/w, TFA 0.003% w/w, sauran kaushi 0.003% w/w da ragowar akan kunnawa 0.00% w/w, bada lissafta tsarki na 0.93 MG na tushen kyauta na peptide a kowace MG na abu akan tushen anhydrous (USP reference-misali takarda, 2023). Misalin aiki kenan, ba takamaiman ba. The counterion kadai yana lissafin fiye da sau biyar nauyin ƙazanta na chromatographic, wanda shine dalilin da ya sa ba za a iya kwatanta adadi mai tsabta da aka nakalto ba tare da ma'auni mai yawa ba a cikin shafuka.
The 2026 bita na ƙimar ingancin peptide da kansa ya sake maimaita bambance-bambance iri ɗaya, ƙara da cewa tsarki yana da alaƙa da ƙazanta masu alaƙa da peptide daidai da API, abin da ke cikin peptide na yanar gizo shine jimillar abubuwan miyagun ƙwayoyi da ƙazanta masu alaƙa da peptide dangane da duk sauran abubuwan, da kuma cewa mafi yawan cikakkun hanyoyin abun ciki ba za su iya bambanta abun da ke cikin miyagun ƙwayoyi daga ƙazantar da ke da alaƙa da peptide ba (Jaridar Binciken Magunguna, 2026). Yana rarraba ƙazanta masu alaƙa da peptide ta asali guda uku, kayan farawa, samuwar a lokacin masana'antu, da lalacewa a lokacin masana'anta ko ajiya, da sunaye nau'ikan ta hanyar inji: gogewa kamar des-Gly-liraglutide, Abubuwan da aka haɗa kamar endo-Gly-liraglutide, maye kamar G10D-liraglutide, Abubuwan da ba su cika-karewa ba kamar su Boc(Nasa)-liraglutide da tert-butylated semaglutide, deamidation kayayyakin kamar [Glu13]-exenatide, stereoisomers kamar 8-D-Ser semaglutide, samfuran oxidation kamar Trp-25-mono-oxidized liraglutide, da tsage-tsafe kamar [14–31]-semaglutide (Jaridar Binciken Magunguna, 2026).
Dacewar Assay wani rikodin daban ne kuma. Ina Q2(R2) yana buƙatar dabarar tabbatarwa da ta dace daga manufar tsarin, ƙayyadaddun bayanai, fasaha da kasada, tare da ƙayyadaddun sharuɗɗan karɓa; ƙayyadaddun ƙayyadaddun ƙayyadaddun ƙazanta dole ne ya nuna mai binciken bai shafe shi da ƙazanta ba, wulakanci, excipients da matrix; madaidaicin dole ne ya haɗa da maimaitawa tare da daidaitattun tsaka-tsaki cikin kwanaki, manazarta, kayan aiki, ginshiƙai da mahalli; kuma dole ne a nuna ƙarfi ba da gangan ba, bambancin gaske a cikin ma'auni mai mahimmanci (Ina Q2(R2), 2023-11-30, errata 2025). Sakamakon tsafta wanda ba a nuna hanyarsa don raba nau'in ƙazanta mai suna daga abin da ake nufi ba ba shigarwar rikodin ce mai karewa ba., komai lambar ta ce.
Abin da ke karya a canja wurin fasaha da haɓakawa lokacin da rikodin rikodin bai cika ba?
Sharhin masana'antu ya bayyana matsalolin fasaha-canja wurin amma bai kafa adadin gazawar canja wurin peptide ba. Yi amfani da ƙayyadaddun ƙayyadaddun canja wurin aiki da rarrabuwar ra'ayi don kimanta yuwuwar aikin.
Lalacewar jadawali yana nunawa a rukunin farko na rukunin yanar gizon. Jagorancin Samsung Biologics MSAT ya bayyana cewa rukunin farko na farko bayan farawa yana ɗaukar watanni shida ko fiye., kuma wannan cikakken dalla-dalla ya tilasta CDMO su ciyar da lokacin tattara shi (Kwangilar Pharma, 2026). Jagora iri ɗaya ya tsara rukunin GMP na kwanaki 90 a matsayin takamaiman, ƙayyadaddun iyaka maimakon tsarin lokaci na yau da kullun, kuma lura cewa canja wurin waje yana ƙara matakan kwangila kamar yarjejeniyar sirri, babban yarjejeniyar sabis da kuma ingancin yarjejeniya kafin fara aikin fasaha (PharmaSource, 2025).
Ka'idodin canja wurin fasaha na WHO ya bayyana ƙaddamarwa a matsayin "hanyar ma'ana da ke sarrafa canja wurin kowane tsari tare da takardunsa da ƙwarewar ƙwararru tsakanin haɓakawa da ƙira ko tsakanin wuraren kera.,” kuma yana buƙatar ƙungiyoyin aikawa da karɓa don tabbatar da haɗin gwiwa cewa bayanan IQ da OQ suna samuwa don kera, marufi da kayan aikin nazari, da cewa dakuna a sashin karba sun cancanta (WHO TRS 961 Annex 7, 2011). Dole ne sashin karɓa kuma ya gudanar da tsarin takaddun da ke da ikon yin rikodin karɓa da gwada samfuran don ƙayyadaddun bayanai ta amfani da hanyoyin gwaji da aka yarda., da na rahoto, yin rikodi da tattara bayanai tare da nadi matsayi (WHO TRS 961 Annex 7, §6.5). Lokacin da rikodin rikodin bai cika ba, cewa ba za a iya kammala tabbatar da haɗin gwiwa ba, da ratar saman a matsayin sake yin aiki yayin cancanta maimakon a matsayin daftarin aiki da ya ɓace.
Wane hukunci mai bita zai iya amfani da shi a benci ko a cikin bitar haɗin gwiwa?
Mai bita na iya gwada kowane rikodin peptide da aka saita tare da tambayoyi uku, kowane mai ganowa zuwa buƙatun mai suna. Na farko, za a iya gano kowane sakamakon da aka ruwaito zuwa tsari, hanya da kayan aikin da suka samar da shi? WHO §6.60 na buƙatar cikakken rikodin duk ɗanyen bayanan da aka samar yayin kowace gwaji, ciki har da jadawali, ginshiƙi da sifofi da aka gano da kyau don nuna takamaiman kayan da aka gwada, da USP <1058> yana buƙatar ƙira kayan ɓangarorin da nau'ikan software waɗanda ke yin chromatogram wanda za'a iya gano shi zuwa ingantaccen tsarin (WHO GMP don APIs, TRS 957 Annex 2, §6.60; LCGC, rashin kwanan wata).
Na biyu, za a iya ganin canji zuwa kowane rikodi ba tare da ɓoyayyen sigar farko ba? 21 CFR 11.10(e) yana buƙatar hanyoyin tantancewa waɗanda ke rikodin kwanan wata da lokacin ayyukan ƙirƙira, gyara ko share bayanan lantarki, tare da canje-canjen da ba su rufe bayanan da aka yi rikodin a baya, kuma 11.70 yana buƙatar sa hannu mai alaƙa da bayanan su don haka ba za a iya cire su ba, kwafi ko akasin haka an canza shi don gurbata rikodin (21 CFR 11.10, halin yanzu kamar na 2026-10-09; 21 Babban darajar CFR 11, halin yanzu kamar na 2026-10-09). WHO §6.60 ta ƙara sa hannu na mutum na biyu wanda ke tabbatar da an sake duba bayanan asali don daidaito, cikawa da yarda (WHO GMP don APIs, TRS 957 Annex 2, §6.60).
Na uku, za a iya samun rukunin yanar gizon sake haifar da yanke shawara daga rikodin shi kaɗai? Wannan yana buƙatar ma'aunin ma'auni a bayan adadi mai tsabta, shaidar asali ta orthogonal, Hanyar abun ciki na peptide, da kuma bayanan tabbatarwa da ke nuna hanyar ta raba nau'in kazanta mai suna (USP reference-misali takarda, 2023; Ina Q2(R2), 2023-11-30). Saitin rikodin da ya wuce duk tambayoyin uku ana iya canjawa wuri. Ɗayan da ya gaza na uku zai kashe lokacin jadawalin a wurin da aka karɓa ba tare da la'akari da yadda kamanni biyu na farko ya cika ba.
Inda taswirar hanyar haɗin gwiwa ta bar ƙungiyoyin peptide a yau?
Taswirar hanyar haɗin gwiwar ta haɓaka fiye da canja wurin fasaha zuwa sarrafa ilimi, samar da abun ciki mai sarrafa kansa, dijital tagwaye, basirar wucin gadi da haɗin gwiwa tare da hukumomin lafiya, tare da maƙasudin da aka bayyana cewa ƙa'idodin da aka haɓaka don ayyukan cikin gida su kasance masu ƙarfi don tallafawa bayanan da aka yi amfani da su wajen ƙaddamar da tsari (Ci gaban Magunguna & Bayarwa, 2026-10-06). Bayanin iyakanta yana ƙaddamar da daidaitattun ƙayyadaddun bayanai na dijital a cikin watanni shida da ƙaddamarwa, kuma kamar na 9 Oktoba 2026 babu data model, sarrafa ƙamus, Ana buga gwajin yarda ko sharuɗɗan (Digital CMC Consortium, 2026-10-09).
Wannan yana barin ƙungiyoyin peptide tare da yanke shawara wanda baya jira akan haɗin gwiwa. An riga an sami bene mai tsari: WHO §6.51-6.52 ta bayyana abun ciki rikodin tsari, §6.60 yana bayyana rikodin kula da dakin gwaje-gwaje, 21 CFR 11.10(e) ya bayyana hanyar tantancewa, da USP <1058> yana bayyana Layer na gano kayan aiki. Gina rikodin da aka saita zuwa waɗannan anka yanzu yana nufin taswirar ƙayyadaddun ƙayyadaddun ƙayyadaddun tsarin haɗin gwiwar zuwa filayen da kuka riga kun cika., maimakon a kan ma'ajin daftarin aiki dole ne a sake tsarawa.
Iyakar gaskiya ita ce ƙungiyar ba ta fitar da jerin abubuwan da suka dace ba, don haka babu wata majiya da ta bayyana ko za a kula da peptides na roba daban da sauran hanyoyin da ke cikin ma'auni. An rubuta buƙatun rikodin WHO don APIs gabaɗaya, kuma babu ɗayan takamaiman tushen peptide da ya bayyana ko waɗannan buƙatun rikodin GMP sun shafi daban-daban ga peptides na roba.. Matsayi mai amfani shine ginawa ga buƙatun gabaɗaya kuma kiyaye takamaiman filayen peptide, jeri, gyare-gyare site da kuma ilmin sunadarai, counterion form, hanyar ganewa, shafi, gradient da zango, a matsayin ƙari za ku iya taswira daga baya.
Tambayoyin da ake yawan yi
Shin ma'auni na Digital CMC Consortium sun zama tilas?
A'a. Ƙungiyar tana aiki kafin gasa da son rai, kuma babu wani ma'auni da aka buga tukuna. Membobin da suka kafa ta sun bayyana aikin a matsayin gina ƙa'idodin dijital na gama gari da abubuwan more rayuwa don bayanin CMC maimakon ba da buƙatun kowa dole ne ya ɗauka., kamar yadda aka bayyana a ciki sanarwar ƙaddamarwa da jerin membobin kafa (2026-10-06). Don ci gaban peptide na shirye-shiryen bayanai, ma'ana haɗin gwiwar hanya ce ta tafiya, ba ranar ƙarshe ba.
Za a iya saita rikodin takarda ya zama shirye-shiryen bayanai?
Ee, muddin dangantakar da kuma hanyar duba sun tsira. 21 Iyakar CFR Sashe na 11 ya ƙunshi bayanai ta hanyar lantarki, yayin da mutuncin tsammanin baya § 11.10(e) hanyoyin tantancewa shafi rikodin ko da kuwa matsakaici. Saitin takarda wanda ke danganta kowane sakamako zuwa ga rabonsa, hanya da kayan aiki suna shirye-shiryen bayanai a cikin abu; saitin da aka bincika tare da fashe hanyoyin haɗin yanar gizo ba.
Nawa ne rikodin rikodin CDMO ke buƙata a kickoff?
Isasshen sake gina tsari, ba komai ba. Mafi ƙarancin shine saitin da aka haɗa: jerin da siga, hanya, m tsari sigogi, hanyoyin nazari tare da ingancin matsayinsu, da kuri'a na asali dangane da su. Matakan baya suna ƙara takamaiman bayanai na ma'auni, amma abokin tarayya wanda ba zai iya ganin dangantaka a kickoff ba zai iya tabbatar da su daga baya.
Shin tsarki yana sama da adadin da aka bayyana ya isa shaidar inganci?
A'a. Tsafta, ainihi, abun ciki/net peptide da kuma dacewa dacewa sune ma'auni daban-daban, kuma ma'anar ma'auni-ma'auni na tsabtataccen peptide ya sanya bambanci kankare: adadi mai tsabta na chromatographic yana kwatanta adadin dangi na nau'in nau'in peptide, ba nawa na kayan shine peptide ba kwata-kwata. Ruwa, counterions da sauran kaushi zama a waje da lambar, don haka babban darajar tsafta ita kaɗai ba ta ce komai game da ainihi ko abun ciki.
Yaya tsawon lokacin da za a adana bayanan kuma ana iya dawo dasu?
Duk tsawon lokacin riƙewa, kuma mai iya dawo da ita gaba dayanta. § 11.10(e) hanyoyin tantancewa yana zaune a cikin wani sashe wanda kuma yana buƙatar bayanan don wanzuwa kuma ana iya karanta su muddin lokacin riƙewa ya ƙare. Saitin rikodin da ya cika a ranar canja wuri amma ba za a iya karantawa ba bayan shekaru uku ya gaza gwadawa iri ɗaya da wanda bai cika ba..
Kammalawa
Ƙungiya tana daidaita ma'auni, kuma mai dubawa yana da kyau kawai kamar rikodin da aka saita a baya. Matsakaicin rikodin haɗin da aka saita don adadin peptide shine WHO §6.51-6.52 abun ciki rikodin tsari, fadada tare da takamaiman filayen peptide don jerin, gyare-gyare site da kuma ilmin sunadarai, counterion form, hanyar ganewa, shafi, gradient da zango, kuma an rufe tare da USP <1058> Layer traceability na kayan aiki da kuma 21 CFR 11.10(e) hanyar tantancewa.
Dokar yanke shawara tambayoyi uku ne: za a iya gano kowane sakamako zuwa rukuninsa, hanya da kayan aiki; za a iya ganin kowane canji ba tare da rufe sigar da ta gabata ba; kuma mai karɓar rukunin yanar gizon zai iya sake haifar da yanke shawara daga rikodin shi kaɗai. Saitin rikodin da ya amsa duka ukun ana iya canjawa wuri yau, kafin ƙungiyar ta buga ƙayyadaddun ta na farko.
Idan kuna shirya fakitin canja wuri kuma kuna son karanta fasaha akan ko saitin rikodin ya amsa waɗannan tambayoyin guda uku, bita tare da masanin fasaha shine mataki na gaba. Ƙungiyar marubucin tana ba da haɗin peptide da sabis na nazari, don haka bita yana ɗaukar sha'awar kasuwanci.
